Patients characteristics | Included pts. (N = 154) N (%) | Pts. with ≥1CTC (N = 118) N (%) | Pts. with ≥1CTC and interpretable FISHc (N =79) N (%) | Pts. with ≥ 1 HER2amp CTC (N = 14) N (%) |
---|---|---|---|---|
Age at inclusion | ||||
≤ 50 years | 26 (17.0%) | 18 (15.4%) | 12 (15.2%) | 3 (21.4%) |
> 50 years | 127 (83.0%) | 99 (84.6%) | 67 (84.8%) | 11 (78.6%) |
NA | 1 | 1 | ||
Performance status | ||||
PS 0 | 63 (44.4%) | 40 (37.4%) | 25 (33.8%) | 3 (21.4%) |
PS 1 | 78 (54.9%) | 66 (61.7%) | 48 (64.9%) | 10 (71.4%) |
PS 2 | 1 (0.7%) | 1 (0.9%) | 1 (1.4%) | 1 (7.1%) |
NA | 12 | 11 | 5 | |
Tumor type | ||||
NST | 135 (89.4%) | 103 (88.8%) | 67 (85.9%) | 13 (92.9%) |
Lobular | 13 (8.6%) | 10 (8.6%) | 10 (12.8%) | 1 (7.1%) |
Other | 3 (2.0%) | 3 (2.6%) | 1 (1.3%) | 0 (0%) |
NA | 3 | 2 | 1 | |
Tumor grade | ||||
Grade I | 10 (7.4%) | 9 (8.7%) | 7 (9.9%) | 2 (16.7%) |
Grade II | 80 (59.3%) | 60 (58.3%) | 44 (62.0%) | 6 (50.0%) |
Grade III | 45 (33.3%) | 34 (33.0%) | 20 (28.2%) | 4 (33.3%) |
NA | 19 | 15 | 8 | 2 |
Receptor status on primary tumor a | ||||
ER− PR− HER2− | 15 (10.1%) | 10 (8.9%) | 6 (8.1%) | 0 (0%) |
ER+ and/or PR+, HER2− | 125 (84.5%) | 98 (87.5%) | 67 (90.5%) | 12 (100%) |
Not done | 8 (5.4%) | 4 (3.6%) | 1 (1.4%) | 0 (0%) |
NA | 6 | 6 | 5 | 2 |
Receptor status on local/distant relapsea | ||||
ER− PR− HER2− | 17 (19.3%) | 10 (15.4%) | 8 (19.5%) | |
ER+ and/or PR+, HER2− | 63 (71.6%) | 49 (75.4%) | 30 (73.2%) | 7 (87.5%) |
Not done | 8 (9.1%) | 6 (9.2%) | 3 (7.3%) | 1 (12.5%) |
NA | 66 | 53 | 38 | 6 |
Number of prior lines of chemotherapyb | ||||
2 | 65 (42.8%) | 46 (39.7%) | 33 (42.3%) | 3 (21.4%) |
3 | 42 (27.6%) | 34 (29.3%) | 20 (25.6%) | 4 (28.6%) |
≥ 4 | 45 (29.6%) | 36 (31.0%) | 25 (32.1%) | 7 (50.0%) |
NA | 2 | 2 | 1 | |
Number of CTC detected | ||||
Screening CTC = 0 | 32 (21.3%) | |||
Screening CTC [1–4] | 32 (21.3%) | 32 (27.1%) | 11 (13.9%) | 0 (0%) |
Screening CTC ≥ 5 | 86 (57.3%) | 86 (72.9%) | 68 (86.1%) | 14 (100%) |
NA | 4 |